Tamoxifen for breast cancer among hysterectomised women

Lancet

Volumn 359, Issue 9312, 2002, Pages 1122-1124

  Veronesi, U ^a   Maisonneuve, P ^a   Sacchini, V ^a   Rotmensz, N ^a   Boyle, P ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MENOPAUSE AND CLIMACTERIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0037197090     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08159-X     Document Type: Article

References (5)

1. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
2. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
4. Drop-outs in tamoxifen prevention trials
5. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer